Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?

References

• Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:118.
   PubMed Web of Science ®Google Scholar
• Biundo F, Del Prete D, Zhang H, et al. A role for tau in learning, memory and synaptic plasticity. Sci Rep. 2018;8:3184.
   PubMed Web of Science ®Google Scholar
• Gomez-Arboledas A, Davila JC, Sanchez-Mejias E, et al. Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer’s disease. Glia. 2018;66:637–653.
   PubMed Web of Science ®Google Scholar
• Apostolova LG, Risacher SL, Duran T, et al. Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis. JAMA Neurol. 2018;75:328–341.
   PubMed Web of Science ®Google Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019;5:272–293.
   Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488:96–99.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501–518.
   PubMed Web of Science ®Google Scholar
• Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space, and “wingmen”. Nat Neurosci. 2015;18:800–806.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73–88.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Amyloid-β immunotherapy for Alzheimer disease: is it now a long shot? Ann Neurol. 2019;85:303–315.
   PubMed Web of Science ®Google Scholar
• Mattsson-Carlgren N, Andersson E, Janelidze S, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease. Sci Adv. 2020;6:eaaz2387.
   PubMed Web of Science ®Google Scholar
• Vogel JW, Iturria-Medina Y, Strandberg OT, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat Commun. 2020;11:2612.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873–2884.
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Gauthier S, Frisoni GB, et al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer’s disease: cohort analysis as modified primary outcome in a phase 3 clinical trial. J Alzheimers Dis. 2018;61:435–457.
   PubMed Web of Science ®Google Scholar
• Schelter BO, Shiells H, Baddeley TC, et al. Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2019;72:931–946.
   PubMed Web of Science ®Google Scholar
• Shiells H, Schelter BO, Bentham P, et al. Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia. J Alzheimers Dis. 2020;75:501–519.
   PubMed Web of Science ®Google Scholar
• Hoskin JL, Sabbagh MN, Al-Hasan Y, et al. Tau immunotherapies for Alzheimer’s disease. Expert Opin Investig Drugs. 2019;28:545–554.
   PubMed Web of Science ®Google Scholar
• Panza F, Logroscino G. Anti-tau vaccine in Alzheimer’s disease: a tentative step. Lancet Neurol. 2017;16:99–100.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18:549–558.
   PubMed Web of Science ®Google Scholar
• Jackson M Biogen’s tau antibody fails in PSP, but Alzheimer’s studies continue. Scrip; 2019 Dec 13.
   Google Scholar
• Carroll J AbbVie scraps an anti-tau study, and that may foretell more big trouble for a beleaguered Biogen. Endpoint News; 2019 Jul 26.
   Google Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9:pii: eaag0481.
   PubMed Web of Science ®Google Scholar
• Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.
   PubMed Web of Science ®Google Scholar
• Therriault J, Benedet AL, Pascoal TA, et al. Association of apolipoprotein E ε4 with medial temporal tau independent of amyloid-β. JAMA Neurol. 2019 Dec 20. DOI:10.1001/jamaneurol.2019.4421. [Epub ahead of print].
   Web of Science ®Google Scholar
• Arboleda-Velasquez JF, Lopera F, O’Hare M, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–1683.
   PubMed Web of Science ®Google Scholar
• Verghese PB, Castellano JM, Garai K, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA. 2013;110:E1807–16.
   PubMed Web of Science ®Google Scholar
• Liu CC, Zhao N, Fu Y, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024–1032.
   PubMed Web of Science ®Google Scholar
• Huynh TV, Liao F, Francis CM, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis. Neuron. 2017;96:1013–1023.
   PubMed Web of Science ®Google Scholar
• Shi Y, Manis M, Long J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216:2546–2561.
   PubMed Web of Science ®Google Scholar
• Kim J, Eltorai AE, Jiang H, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J Exp Med. 2012;209:2149–2156.
   PubMed Web of Science ®Google Scholar
• Liao F, Li A, Xiong M, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest. 2018;128:2144–2155.
   PubMed Web of Science ®Google Scholar
• Rosenberg JB, Kaplitt MG, De BP, et al. AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer’s disease. Hum Gene Ther Clin Dev. 2018;29:24–47.
   PubMed Web of Science ®Google Scholar
• Corlier F, Hafzalla G, Faskowitz J, et al. Systemic inflammation as a predictor of brain aging: contributions of physical activity, metabolic risk, and genetic risk. Neuroimage. 2018;172:118–129.
   PubMed Web of Science ®Google Scholar
• Warren KN, Beason-Held LL, Carlson O, et al. Elevated markers of inflammation are associated with longitudinal changes in brain function in older adults. J Gerontol A Biol Sci Med Sci. 2018;73:770–778.
   PubMed Web of Science ®Google Scholar
• Marsland AL, Gianaros PJ, Kuan DC, et al. Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav Immun. 2015;48:195–204.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. An update on the efficacy of Non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opin Investig Drugs. 2009;18:1147–1168.
   PubMed Web of Science ®Google Scholar
• Hampel H, Caraci F, Cuello CA. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456.
   PubMed Web of Science ®Google Scholar
• Chetty A, Sharda A, Warburton R, et al. A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma. J Asthma Allergy. 2018;11:159–171.
   PubMed Web of Science ®Google Scholar
• Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science. 2003;301:1895–1898.
   PubMed Web of Science ®Google Scholar
• Yli-Karjanmaa M, Larsen KS, Fenger CD, et al. TNF deficiency causes alterations in the spatial organization of neurogenic zones and alters the number of microglia and neurons in the cerebral cortex. Brain Behav Immun. 2019;82:279–297.
   PubMed Web of Science ®Google Scholar
• Sama DM, Mohmmad Abdul H, Furman JL, et al. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS One. 2012;7:e38170.
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–489.
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20:pii: E3328.
   PubMed Web of Science ®Google Scholar
• Kirkland JL, Tchkonia T, Zhu Y, et al. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65:2297–2301.
   PubMed Web of Science ®Google Scholar
• Wissler Gerdes EO, Zhu Y, Tchkonia T, et al. Discovery, development, and future application of senolytics: theories and predictions. Febs J. 2020 Feb 29;287:2418–2427. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Biber K, Moller T, Boddeke E, et al. Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov. 2016;15:110–124.
   PubMed Web of Science ®Google Scholar
• Brennan FH, Lee JD, Ruitenberg MJ, et al. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol. 2016;28:292–308.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ippati S, Ceravolo F, et al. Perspective: is therapeutic plasma exchange a viable option for treating Alzheimer’s disease? Alzheimers Dement;2020. DOI:10.1002/trc2.12004. in press.
   Google Scholar
• Middeldorp J, Lehallier B, Villeda SA, et al. Preclinical assessment of young blood plasma for Alzheimer disease. JAMA Neurol. 2016;73:1325–1333.
   PubMed Web of Science ®Google Scholar
• Lopez OL. AMBAR (Alzheimer’s management by albumin replacement) phase IIb/III results. J Prev Alzheimers Dis. 2018;5(Suppl 1):S8.
   PubMedGoogle Scholar
• Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;146:682–695.
   PubMed Web of Science ®Google Scholar
• Boyle PA, Yang J, Yu L, et al. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140:804–812.
   PubMed Web of Science ®Google Scholar
• Lonskaya I, Hebron ML, Desforges NM, et al. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med. 2014;92:373–386.
   PubMed Web of Science ®Google Scholar
• Turner RS, Hebron ML, Lawler A, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Ann Neurol. 2020;88:183–194.
   PubMed Web of Science ®Google Scholar
• Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem. 2017;143:418–431.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis. 2018;62:1403–1416.
   PubMed Web of Science ®Google Scholar
• Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69:836–841.
   PubMed Web of Science ®Google Scholar
• Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. Faseb J. 2008;22:703–712.
   PubMed Web of Science ®Google Scholar
• Atamna H, Mackey J, Dhahbi JM. Mitochondrial pharmacology: electron transport chain bypass as strategies to treat mitochondrial dysfunction. Biofactors. 2012;38:158–166.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (Methylene Blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8:609–622.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang S, Maezawa I, et al. Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer’s disease. EBioMedicine. 2015;2:294–305.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet. 2017;26:1483–1496.
   PubMed Web of Science ®Google Scholar
• Sebastiao I, Candeias E, Santos MS, et al. Insulin as a bridge between type 2 diabetes and Alzheimer disease: how anti-diabetics could be a solution for dementia. Front Endocrinol. 2014;5:110.
   PubMed Web of Science ®Google Scholar
• McIntosh EC, Nation DA. Alzheimer’s disease neuroimaging initiative. Importance of treatment status in links between type 2 diabetes and Alzheimer’s disease. Diabetes Care. 2019;42:972–979.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. In Alzheimer research, glucose metabolism moves to center stage. JAMA. 2020 Jan 8. DOI:10.1001/jama.2019.20939. [Epub ahead of print].
   Web of Science ®Google Scholar
• Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre. Brain. 2013;136:2697–2706.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12:723–738.
   PubMed Web of Science ®Google Scholar
• Brunet A, Berger SL. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci. 2014;69(suppl 1):S17–S20.
   PubMedGoogle Scholar
• Delgado-Morales R, Agis-Balboa RC, Esteller M, et al. Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. Clin Epigenetics. 2017;9:67.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiao B, Shen L. The epigenetics of Alzheimer’s disease: factors and therapeutic implications. Front Genet. 2018;9:579.
   PubMed Web of Science ®Google Scholar
• Maes T, Molinero C, Antonijoan RM, et al. First-in-human phase I results show safety, tolerability and brain penetrance of ORY-2001, an epigenetic drug targeting LSD1 and MAO-B. Alzheimers Dement. 2017;13:P1573–P1574.
   Google Scholar
• Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci. 2012;13:240–250.
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Schmitt FA, et al. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372–1384.
   PubMed Web of Science ®Google Scholar
• van Deijk AF, Broersen LM, Verkuyl JM, et al. High content analysis of hippocampal neuron-astrocyte co-cultures shows a positive effect of fortasyn connect on neuronal survival and postsynaptic maturation. Front Neurosci. 2017;11:440.
   PubMed Web of Science ®Google Scholar
• Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:965–975.
   PubMed Web of Science ®Google Scholar
• Jiang C, Li G, Huang P, et al. The gut microbiota and Alzheimer’s disease. J Alzheimers Dis. 2017;58:1–15.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Vojdani E, Saidara E, et al. Reaction of amyloid-β peptide antibody with different infectious agents involved in Alzheimer’s disease. J Alzheimers Dis. 2018;63:847–860.
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Solfrizzi V, et al. Time to test antibacterial therapy in Alzheimer’s disease. Brain. 2019b;142:2905–2929.
   PubMed Web of Science ®Google Scholar
• Morris JC. Editorial: is now the time for combination therapies for Alzheimer disease? J Prev Alzheimers Dis. 2019;6:153–154.
   PubMed Web of Science ®Google Scholar
• Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, et al. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer s disease like phenotype of a commonly used mouse model. Curr Pharm Des. 2013;19:5076–5084.
   PubMed Web of Science ®Google Scholar
• Dionisio PA, Amaral JD, Ribeiro MF, et al. Amyloid β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015;36:228–240.
   PubMed Web of Science ®Google Scholar
• Roche provides topline results from investigator-led phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease. cited 2020 May 18 Available from: ttps://www.roche.com/media/releases/med-cor-2020-02-10.htm
   Google Scholar
• Mattsson N, Cullen N, Andreasson U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76:791–799.
   PubMed Web of Science ®Google Scholar
• Amadoro G, Latina V, Corsetti V, et al. N-terminal tau truncation in the pathogenesis of Alzheimer’s Disease (AD): developing a novel diagnostic and therapeutic approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165584.
   PubMed Web of Science ®Google Scholar
• Corsetti V, Borreca A, Latina V, et al. Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models. Brain Commun. 2020 Apr 6;2. DOI:10.1093/braincomms/fcca039.
   PubMedGoogle Scholar
• Vasanthakumar A, Davis JW, Idler K, et al. Harnessing peripheral DNA methylation differences in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Clin Epigenetics. 2020;12:84.
   PubMed Web of Science ®Google Scholar